JBIO
Jade Biosciences, Inc. NASDAQ$25.26
Mkt Cap $824.1M
52w Low $6.57
87.2% of range
52w High $28.00
50d MA $17.36
200d MA $12.63
P/E (TTM)
-6.0x
EV/EBITDA
-3.5x
P/B
2.3x
Debt/Equity
0.0x
ROE
-38.3%
P/FCF
-5.1x
RSI (14)
—
ATR (14)
—
Beta
1.03
50d MA
$17.36
200d MA
$12.63
Avg Volume
477.6K
About
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data exp…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | AMC | -0.45 | -0.11 | +75.6% | 14.05 | +2.8% | +2.7% | +3.1% | -0.2% | -1.4% | -0.9% | — |
| Nov 13, 2025 | AMC | -0.57 | -0.48 | +15.8% | 9.68 | -0.8% | +10.5% | +30.1% | +30.7% | +28.7% | +18.6% | — |
| Aug 13, 2025 | AMC | -0.43 | -0.86 | -100.0% | 7.33 | +5.9% | -7.6% | +0.4% | +2.3% | +0.4% | -6.5% | — |
| Apr 25, 2025 | AMC | -8.40 | -0.09 | +98.9% | 93.80 | -0.7% | +0.0% | -89.2% | -89.9% | -89.3% | -86.7% | — |
| Mar 27, 2025 | AMC | -0.19 | -0.19 | +0.0% | 88.55 | +0.8% | +0.0% | -0.8% | -0.8% | -0.4% | -0.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.98 | $25.78 | +3.2% | +7.5% | +5.9% | -10.6% | -2.3% | -3.0% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.26 | $13.58 | +2.4% | +5.2% | +5.2% | +1.0% | +0.0% | +6.0% |
| Mar 16 | BTIG | Maintains | Buy → Buy | — | $13.92 | $14.79 | +6.2% | +2.4% | +0.4% | -1.0% | +1.1% | +0.6% |
| Mar 11 | Guggenheim | Maintains | Buy → Buy | — | $14.48 | $14.90 | +2.9% | -3.2% | -4.3% | -3.9% | -1.6% | -3.5% |
| Mar 9 | Wedbush | Maintains | Outperform → Outperform | — | $14.05 | $14.44 | +2.8% | +2.7% | +3.1% | -0.2% | -1.4% | -0.9% |
| Nov 18 | Guggenheim | Maintains | Buy → Buy | — | $12.59 | $12.84 | +2.0% | +0.5% | -1.0% | -8.8% | -4.7% | -3.5% |
| Aug 14 | Wedbush | Maintains | Outperform → Outperform | — | $7.33 | $7.76 | +5.9% | -7.6% | +0.4% | +2.3% | +0.4% | -6.5% |
| Jun 16 | Guggenheim | Upgrade | Neutral → Buy | — | $6.76 | $7.25 | +7.2% | +3.4% | +22.6% | +39.2% | +46.3% | +46.0% |
| May 15 | Wedbush | Maintains | Outperform → Outperform | — | $7.55 | $7.50 | -0.7% | -2.0% | -2.8% | -1.7% | +2.3% | -0.8% |
Recent Filings
8-K
Jade Biosciences, Inc. -- 8-K Filing
I cannot provide a meaningful analysis from this filing summary, as it contains only standard incorporation and address information without disclosing any material business events or transactions affecting Jade Biosciences investors.
Apr 22
8-K
Unknown — 8-K Filing
Jeanerette BioVentures is implementing a 2026 equity incentive plan to attract new employees, signaling management confidence in growth plans but potentially diluting existing shareholders through future stock issuances.
Apr 2
8-K
Jade Biosciences, Inc. -- 8-K Filing
Jade Biosciences (JBIO) advanced its clinical pipeline in 2025 by initiating a Phase 1 study for JADE101 and progressing JADE201 toward clinical development, signaling continued pipeline momentum for its autoimmune disease therapies.
Mar 6
Data updated apr 25, 2026 4:43pm
· Source: massive.com